Wed, December 17, 2008
Tue, December 16, 2008
Mon, December 15, 2008
Sun, December 14, 2008
Fri, December 12, 2008
Thu, December 11, 2008
Wed, December 10, 2008
Tue, December 9, 2008
Mon, December 8, 2008
Sun, December 7, 2008
Sat, December 6, 2008
Fri, December 5, 2008
Thu, December 4, 2008
Wed, December 3, 2008
[ Wed, Dec 03rd 2008 ]: Market Wire
Protherics PLC: Offer Update
Tue, December 2, 2008
Mon, December 1, 2008
Sun, November 30, 2008
Fri, November 28, 2008
Thu, November 27, 2008
Wed, November 26, 2008
Tue, November 25, 2008
Mon, November 24, 2008
Thu, November 20, 2008
Wed, November 19, 2008
Tue, November 18, 2008

ImmunoGen, Inc. Announces Webcast of Panel Session at the RBC Capital Markets 2008 Healthcare Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2008/ .. -capital-markets-2008-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire


WALTHAM, Mass.--([ BUSINESS WIRE ])--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Daniel Junius, President and Chief Operating Officer, will participate on the panel, The Power of Collaboration: Genentech and Its Partners, at the RBC Capital Markets 2008 Healthcare Conference. This 55-minute panel session will begin at 10:00 am EST on Thursday, December 11, 2008, and will be webcast live. The Conference will take place at the Westin New York at Times Square hotel in New York City.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and a naked antibody AVE1642 is in clinical trials through the Company's collaboration with sanofi-aventis. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.


Publication Contributing Sources

Similar Health and Fitness Publications